Selected Articles from This Issue

Abstract

Highlights| October 03 2022 Selected Articles from This Issue Author & Article Information Online ISSN: 1557-3265 Print ISSN: 1078-0432 ©2022 American Association for Cancer Research2022American Association for Cancer Research Clin Cancer Res (2022) 28 (19): 4159. https://doi.org/10.1158/1078-0432.CCR-28-19-HI Related Content A commentary has been published: Clinical, Pathologic, and Molecular Prognostic Factors in Patients with Early-Stage EGFR-Mutant NSCLC A commentary has been published: Detection of Occult Recurrence Using Circulating Tumor Tissue Modified Viral HPV DNA among Patients Treated for HPV-Driven Oropharyngeal Carcinoma A commentary has been published: Microsatellite Instability–High Endometrial Cancers with MLH1 Promoter Hypermethylation Have Distinct Molecular and Clinical Profiles View more A commentary has been published: OLIG2 Is a Determinant for the Relapse of MYC-Amplified Medulloblastoma View less Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn MailTo Tools Icon Tools Get Permissions Cite Icon Cite Search Site Article Versions Icon Versions Version of Record October 3 2022 Citation Selected Articles from This Issue. Clin Cancer Res 1 October 2022; 28 (19): 4159. https://doi.org/10.1158/1078-0432.CCR-28-19-HI Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest Search Advanced Search Patients with MYC-amplified medulloblastoma (MB) have poor prognosis and frequently develop recurrence; thus new therapeutic approaches to prevent recurrence are needed. Here, Xu and colleagues demonstrate that OLIG2-expressing tumor cells are highly enriched in therapy resistant and recurrent MYC-amplified MB and high levels of OLIG2 correlated with poor prognosis. Genetic or pharmacological inhibition of OLIG2 in combination with radiotherapy significantly suppressed the progression of OLIG2-high tumors in patient-derived xenograft mouse models, indicating that OLIG2 represents a novel therapeutic target in high-risk MB. CT-179 is a highly potent and selective small molecule OLIG2 inhibitor. The study provides evidence for CT-179 to potentially act as an adjunctive therapy for patients with high-risk MB as well as other types of pediatric brain tumors where OLIG2 is highly expressed. Thus patients with these cancers may also benefit from CT-179 treatment. Cell-free tumor tissue modified viral (TTMV)-HPV DNA is a unique biomarker, present... You do not currently have access to this content.